TRANSCODE THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
TRANSCODE THERAPEUTICS, INC. (RNAZ) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $485.43 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- TRANSCODE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $134.32K, a 34.31% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $131.51K, a 88.50% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $157.73K, a 13.88% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $204.48K, a 47.88% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $485.43K, a 71.45% decline from fiscal 2024.
- TRANSCODE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.70M, a 63.95% increase from fiscal 2023.
- TRANSCODE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.04M, a 162.29% increase from fiscal 2022.
- TRANSCODE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $395.33K, a 112.55% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $485.43K 10-K · filed 2026-04-15 | |||
| 2025-09-30 | $134.32K 10-Q · filed 2025-11-14 | $265.83K derived: sum of 2 quarters · filed 2026-08-14 | $423.56K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $131.51K 10-Q · filed 2026-08-14 | $289.24K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $157.73K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $1.70M 10-K · filed 2026-04-15 | |||
| 2024-09-30 | $204.48K 10-Q · filed 2025-11-14 | $1.35M derived: sum of 2 quarters · filed 2025-11-14 | $1.53M derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $1.14M 10-Q · filed 2025-11-14 | $1.33M derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $183.15K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $1.04M 10-K · filed 2025-04-15 | |||
| 2023-09-30 | $392.33K 10-Q · filed 2024-11-14 | $567.82K derived: sum of 2 quarters · filed 2024-11-14 | $726.58K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $175.48K 10-Q · filed 2024-11-14 | $334.24K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $158.76K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $395.33K 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $105.60K 10-Q · filed 2023-11-14 | $204.20K derived: sum of 2 quarters · filed 2023-11-14 | $264.77K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $98.60K 10-Q · filed 2023-11-14 | $159.17K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $60.57K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $186.00K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $64.05K 10-Q · filed 2022-11-14 | $98.56K derived: sum of 2 quarters · filed 2022-11-14 | $147.00K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $34.51K 10-Q · filed 2022-11-14 | $82.94K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $48.43K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $45.44K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $31.38K 10-Q · filed 2021-11-15 | $32.08K derived: sum of 2 quarters · filed 2021-11-15 | $32.78K derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $699.00 10-Q · filed 2021-11-15 | $1.40K derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $698.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |